Research Atlas · source screening

Ixazomib

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

333

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Ixazomib"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Preclinical evaluation of ixazomib for high-risk pediatric brain tumors.

   bioRxiv · 2026 Sep 18 · PMID 42779611 · DOI 10.64898/2026.09.11.750478

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study.

   Haematologica · 2026 Sep 10 · PMID 42719971 · DOI 10.3324/haematol.2026.301067

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens.

   Cancer Med · 2026 Sep · PMID 42779200 · DOI 10.1002/cam4.72314

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

   Br J Haematol · 2026 Aug 30 · PMID 42669938 · DOI 10.1111/bjh.70806

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta-analysis.

   Br J Haematol · 2026 Aug 23 · PMID 42633972 · DOI 10.1111/bjh.70757

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

   Blood Neoplasia · 2026 Aug · PMID 42376206 · DOI 10.1016/j.bneo.2026.100247

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

   Clin Lymphoma Myeloma Leuk · 2026 Aug · PMID 42315418 · DOI 10.1016/j.clml.2026.05.004

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.

   Mol Oncol · 2026 Aug · PMID 41987550 · DOI 10.1002/1878-0261.70256

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma.

   Blood Cancer J · 2026 Jul 18 · PMID 42471354 · DOI 10.1038/s41408-026-01567-y

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.

    Clin Lymphoma Myeloma Leuk · 2026 Jul · PMID 42209393 · DOI 10.1016/j.clml.2026.04.025

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.

    Br J Haematol · 2026 Jul · PMID 42097596 · DOI 10.1111/bjh.70512

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.

    Leuk Res · 2026 Jul · PMID 42001677 · DOI 10.1016/j.leukres.2026.108236

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Unusual Periorbital Edematous Erythema: Ixazomib-Induced Histiocytoid Sweet's Syndrome.

    Int J Dermatol · 2026 Jul · PMID 41491593 · DOI 10.1111/ijd.70242

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.

    Am J Hematol · 2026 Jun · PMID 41714853 · DOI 10.1002/ajh.70239

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

    Haematologica · 2026 May 28 · PMID 42206445 · DOI 10.3324/haematol.2026.300897

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.

    Mol Cancer · 2026 May 27 · PMID 42204603 · DOI 10.1186/s12943-026-02689-4

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

    Clin Cancer Res · 2026 May 15 · PMID 42007903 · DOI 10.1158/1078-0432.CCR-25-4518

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Ixazomib triggers autophagic degradation of MUC5AC/integrin-β4 and inhibits non-small cell lung cancer progression.

    Cancer Lett · 2026 May 1 · PMID 41771342 · DOI 10.1016/j.canlet.2026.218333

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Lisaftoclax combined with ixazomib and dexamethasone after CAR-T for maintenance therapy in transplant-ineligible relapsed/refractory ultra-high-risk multiple myeloma: two case reports and literature review.

    Front Oncol · 2026 · PMID 42130633 · DOI 10.3389/fonc.2026.1784393

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.

    Res Sq · 2026 Apr 23 · PMID 42078883 · DOI 10.21203/rs.3.rs-9405584/v1

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers.

    Haematologica · 2026 Apr 1 · PMID 41098101 · DOI 10.3324/haematol.2025.288320

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference Group.

    In Vivo · 2026 Mar-Apr · PMID 41760321 · DOI 10.21873/invivo.14257

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms.

    Ther Adv Hematol · 2026 · PMID 41782904 · DOI 10.1177/20406207261421841

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.

    NPJ Precis Oncol · 2026 Feb 26 · PMID 41748936 · DOI 10.1038/s41698-026-01332-1

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. "Et tu, Brute?" -A Case of Ixazomib-Induced Cancer Therapy-Related Cardiac Dysfunction.

    Intern Med · 2026 Feb 24 · PMID 41730625 · DOI 10.2169/internalmedicine.6894-25

    Source metadata only · evidence grade unassigned · scientific conclusions pending review